CME Webcast

Gout and Your Patients: Diagnosis, Treatment, and Management

For AAFP members only

Picture of doctor examining patient's foot on laptop

The prevalence of gout continues to increase, with 3.9% of the U.S. population being affected. While gout is painful and troublesome on its own, the condition might also serve as a signal of other unrecognized comorbidities. Learn the latest evidence-based recommendations and guidelines to better assess and care for your patients who have gout.

Watch this hour-long webcast and earn 1 AAFP Prescribed credit. This activity is free for AAFP members.

Enhance your patient care today and earn up to 2 additional AAFP Prescribed credits when you complete the Translation to Practice® (t2p) process. Plus, get access to the online gout learning community that promotes additional peer-to-peer learning.

About the Webcast

Learning Objectives

After completing this CME activity, you should be able to:

  • Describe the pathogenesis of gout, noting risk factors and points where therapeutic agents impact disease biochemistry.
  • Implement a care plan for the diagnosis and treatment of gout, which takes into account acute management of gouty flairs and chronic management of associated risk factors.
  • Evaluate how your management plan should be individualized for each patient, including a consideration of the specific needs of special populations.

Original release date of webcast: April 29, 2016

Flash Player is required to view this webcast. Some mobile devices may not be compatible. View the system requirements.

Presenting Faculty

Pamela G. Rockwell, DO, Assistant Professor, Department of Family Medicine, University of Michigan; Medical Director, Domino’s Farms Family Medicine


This CME activity is funded by an educational grant to the AAFP from AstraZeneca.

Have you completed this Webcast?

Begin Translation to Practice process »

(log-in required)

Online Learning Community

After starting t2p, visit the learning community on gout that promotes additional peer-to-peer learning.
Access now »

(log-in required)

CME Credit

To be eligible to report CME credit, please complete the full module in one sitting.

This enduring material activity, Gout and Your Patients: Diagnosis, Treatment, and Management, has been reviewed and is acceptable for up to 1 Prescribed credit by the American Academy of Family Physicians. Term of approval begins April 29, 2016. Term of approval is for two years from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The AAFP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Family Physicians designates this enduring material activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Following this CME activity, participants have the opportunity to earn two additional credits by participating in a Translation to Practice® exercise. Information on Translation to Practice® (t2p™) will be shared within the activity.

CME activities approved for AAFP credit are recognized by the AOA as equivalent to AOA Category 2 credit.


The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.

The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.

Off-Label Uses

The faculty for this activity have made all reasonable efforts to ensure the information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation. Information regarding drugs (eg, administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and delivery systems is subject to change.

The reader is advised to check the manufacturer’s insert and medical references for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering any drug.

The content of this material/presentation in this CME activity includes discussion of unapproved or investigational uses of products or devices: Lorsartan and Fenofribrate used off-label for mild disease.

Have you completed this Webcast?

Begin Translation to Practice process »

(log-in required)